Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process

EMERYVILLE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company, announced today both the nationwide launch of its breakthrough Lucira COVID-19 & Flu Home Test in the United States, as well as the combination test’s inclusion in the Australian Register of Therapeutic Goods (ARTG) for use by healthcare professionals in a point-of-care setting. The COVID-19 & Flu Home Test is the first and only combination COVID-19 & Flu test to be granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for over the counter (OTC) use at home and other non-laboratory sites. The Lucira COVID-19 & Flu Home Test is a molecular test that demonstrated similar performance for COVID-19 and Influenza compared to highly sensitive lab-based PCR tests in clinical trials. The easy-to-use, all-in-one combination test delivers results in 30 minutes or less from one shallow nasal swab, and as of today can be purchased in the United States for the introductory price of $34.99 at www.lucirahealth.com/flu.

Read more at globenewswire.com